Dare Bioscience (DARE) Total Liabilities (2013 - 2026)
Dare Bioscience's (DARE) quarterly Total Liabilities came in at $29.6 million in Q4 2025, up 5.4% YoY from $28.1 million in Q4 2024, and up 6.24% on a QoQ basis from $27.9 million in Q3 2025.
Dare Bioscience (DARE) Total Liabilities (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Total Liabilities data on file, last reported at $29.6 million in Q4 2025.
- Quarterly Total Liabilities rose 5.4% year-over-year to $29.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.6 million (up 5.4% YoY) and the FY2025 annual result came in at $29.6 million, up 5.4% from the prior year.
- Total Liabilities advanced to $29.6 million in Q4 2025, from $27.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $32.7 million in Q4 2022 to a low of $7.1 million in Q2 2021.
- A 5-year average of $22.5 million and a median of $24.7 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 159.39% — and 2024, when it slipped 28.52%.
- Tracing DARE's Total Liabilities over 5 years: stood at $17.1 million in 2021, then surged by 91.84% to $32.7 million in 2022, then declined by 19.52% to $26.3 million in 2023, then gained by 6.77% to $28.1 million in 2024, then advanced by 5.4% to $29.6 million in 2025.
- The last three Total Liabilities figures came in at $29.6 million (Q4 2025), $27.9 million (Q3 2025), and $25.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 10.03 Bn |
| 10 | Dare Bioscience | 12.06 Mn | -555,340.81 | -132,343.00 | 22.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.93 Mn |
| Dec 31, 2025 | 29.63 Mn |
| Sep 30, 2025 | 27.89 Mn |
| Jun 30, 2025 | 25.71 Mn |
| Mar 31, 2025 | 28.18 Mn |
| Dec 31, 2024 | 28.11 Mn |
| Sep 30, 2024 | 19.54 Mn |
| Jun 30, 2024 | 20.93 Mn |
| Mar 31, 2024 | 24.01 Mn |
| Dec 31, 2023 | 26.33 Mn |
| Sep 30, 2023 | 27.34 Mn |
| Jun 30, 2023 | 25.93 Mn |
| Mar 31, 2023 | 25.40 Mn |
| Dec 31, 2022 | 32.71 Mn |
| Sep 30, 2022 | 24.03 Mn |
| Jun 30, 2022 | 18.36 Mn |
| Mar 31, 2022 | 18.31 Mn |
| Dec 31, 2021 | 17.05 Mn |
| Sep 30, 2021 | 16.92 Mn |
| Jun 30, 2021 | 7.08 Mn |